Page 120 - Merck Sharp News Today

Lenvatinib plus pembrolizumab improves long-term outcomes, compared with sunitinib alone, in patients with advanced renal cell carcinoma.

Five things you need to know about the coronavirus pandemic this Friday evening.

It marks the first authorisation from a public health body for oral antiviral treatment for Covid.

Pfizer says its antiviral pill 89% effective in high-risk Covid cases

The company stopped clinical trials early because initial results for the drug were so positive.

COPENHAGEN, Denmark, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve

The antiviral Lagevrio (molnupiravir) is safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease, the Medicines and Healthcare products Regulatory Agency announced today.

Washington - An experimental pill to treat coronavirus (COVID-19) developed by the United States company Pfizer cuts the risk of hospitalisation or death by 89 per cent in vulnerable adults, clinical trial results suggest. The drug - Paxlovid - is intended for use soon after symptoms develop in people at high risk of severe disease. It comes a day after the United Kingdom medicines regulator approved a similar treatment from Merck Sharp …

The UK has become the first country to approve Merck's game changing pill to treat COVID.

The UK has approved antiviral COVID-19 drug Lagevrio (molnupiravir) after it was found to be safe and effective at reducing the risk of hospitalisation and deat